WillItSurvive
Medical technology and health companies · United States

Hinge Health

hingehealth.com ↗

Digital clinic for back, joint, and muscle pain using wearable sensors, coaches, and an app.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from Aug 4, 2026 · Every call on the record Checkpoint: Q2 2026 earnings call, watch revenue growth vs 45%+ guidance and gross margin vs 84%
The call

Hinge Health sits on locked-in health plan contracts and hardware data that AI rivals like Sword Health are still trying to match.

Hinge Health sells an FDA-approved device called Enso that guides patients through physical therapy exercises at home, paired with software that tracks progress. The company is difficult to copy because it has locked in long-term deals with all five biggest U.S. health insurers, has built up 25 million eligible patients across its network, and collects detailed outcome data showing the treatment works; competitors like Teladoc can bundle similar services but face conflicts selling to the same insurers, while traditional physical therapy clinics cannot match the home-based economics. The picture could shift if Sword Health, a rival company that just bought Kaia for $285 million in early 2026, starts winning over the same big health plans or if three of the five largest insurers decide to build their own competing programs instead of staying with Hinge.

Why
01
AI pressure: Sword Health (AI-native MSK competitor, post-Kaia acquisition). Sword uses AI-driven coaching to underbid on price; its Kaia integration could shift enterprise win rates away from Hinge if it delivers similar outcomes cheaper. Could AI do the core job? Unlikely.
02
Bigger players: Teladoc Health. Teladoc could bundle a cheaper MSK feature into its chronic-care suite, but it lacks Hinge's outcomes data and health-plan contracts to match clinical results. Could a giant copy it? Probably.
03
What protects it. FDA-cleared Enso device plus multi-year exclusive contracts with all five largest US health plans and years of outcomes data competitors can't replicate fast.
What would change this call
Any top-5 national health plan cancels or lets its Hinge contract lapse without renewal. Would show incumbents building internal MSK tools instead of partnering with Hinge.
Sword Health reports 2+ consecutive quarters of new enterprise logo wins over Hinge post-Kaia integration. Would show Sword converting acquisition into real share gains against Hinge.
Hinge's Q2 2026 earnings (Aug 4) gross margin falls materially below 80%. Would show Enso hardware costs outpacing efficiency gains, weakening the profitability moat.
Key numbers
  • Q4 2025 revenue $170.7M, up 46% YoY (2025-Q4)
  • GAAP gross margin 84% in Q4 2025 (2025-Q4)
  • 2,560 enterprise clients, up 25% YoY (2025-Q3)
Named risks
  • Top health plan clients could build internal MSK products instead of renewing partnerships. Severity: high
  • Sword Health's Kaia acquisition (Jan 2026) could accelerate new-logo share competition. Severity: medium
  • Large GAAP net losses tied to IPO-related stock compensation charges cloud profitability picture. Severity: medium
  • Headcount declining (-2.0% YoY to Dec 2025) while member base and revenue scale rapidly. Severity: low
  • Enso hardware rollout expansion (migraine, surgery) could pressure gross margins if AI efficiency gains lag. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Sword Healthgaining onAcquired rival Kaia Health for $285M on Jan 28, 2026, consolidating digital MSK market
Kaia Healthlosing toAbsorbed into Sword Health via $285M acquisition, Jan 2026
Teladoc HealthcontestingBundling MSK-adjacent chronic care into telehealth suites post-Livongo integration
Omada HealthcontestingPositioned by benefits managers as bundled chronic-condition alternative to Hinge
Questions people ask
Is Hinge Health profitable in 2025?
Yes on key operating metrics. Hinge Health turned net-income positive in Q1 2025 with an 81% gross margin, and by Q4 2025 (reported Feb 10, 2026) GAAP gross margin reached 84% on revenue of $170.7 million, up 46% year over year.
Is Hinge Health a public company now?
Yes. Hinge Health IPO'd on the NYSE under ticker HNGE on May 22, 2025, pricing at $32/share, the top of its $28-32 range, raising roughly $437-503 million and popping 17-23% to close near $37.56 on debut.
Who is Hinge Health's biggest competitor?
Sword Health is Hinge Health's closest direct rival in digital musculoskeletal care. Sword acquired competitor Kaia Health for $285 million on January 28, 2026, consolidating the market, though Hinge still leads on scale with 2,800+ clients and 25 million eligible lives as of Q4 2025.
Could AI replace Hinge Health's core product?
Unlikely soon. While AI drives exercise-form correction and coaching, Hinge's moat rests on FDA-cleared Enso hardware, typically three-year exclusive enterprise contracts, and partnerships with all five largest US health plans, things a pure AI/software entrant cannot quickly replicate as of 2026.
Has Hinge Health had layoffs?
Yes, Hinge Health laid off approximately 10% of its workforce (then over 1,700 employees) in April 2024. Headcount has stayed roughly flat since, estimated at 1,582 as of December 2025 per Revelio Labs, down 2.0% year over year, even as revenue grew sharply.
How fast is Hinge Health growing?
Hinge Health's revenue grew 46% year over year in Q4 2025 to $170.7 million, and 53% year over year in Q3 2025 to $154 million, reported via its investor relations site on February 10, 2026 and November 4, 2025 respectively.
Timeline
  • 2026-06-10Expanded HingeSelect to include orthopedic surgery, covering full MSK journey
  • 2026-04-29FDA cleared Enso for migraine; launched Migraine Care Program
  • 2026-02-10Q4/FY2025 results: $170.7M revenue, +46% YoY, 84% GAAP gross margin
  • 2026-01-28Sword Health acquired rival Kaia Health for $285 million
  • 2025-11-04Q3 2025 results: $154M revenue, +53% YoY, 1.5M+ lifetime members
  • 2025-05-22IPO on NYSE (HNGE) at $32/share, closed up 17-23% to ~$37.56
  • 2024-09-09Launched Enso 3, new wearable hardware iteration
  • 2024-04-11Laid off approximately 10% of workforce
  • 2021-01-07Raised $300M Series D at $3B valuation, led by Coatue and Tiger Global
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources